Fundraising Support, Upcoming Conferences, Clinical Data Presentations, and Cash Dividends - Analyst Notes on WellCare, NPS Pharma, Merrimack Pharmaceuticals, CONMED and Haemonetics

NEW YORK, May 28, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding WellCare Health Plans, Inc. (NYSE: WCG), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Merrimack Pharmaceuticals Inc (NASDAQ: MACK), CONMED Corporation (NASDAQ: CNMD) and Haemonetics Corporation (NYSE: HAE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3014-100free.

--
WellCare Health Plans, Inc. Analyst Notes
On May 20, 2014, WellCare Health Plans, Inc. (WellCare) reported that 'Ohana Health Plan, a health plan offered by WellCare, together with its associates, donated almost $9,000 to support Hospice Hawaii's 5th Annual Hot Pursuit competition - an event created to help the organization provide quality end-of-life and palliative care to patients and their families. According to the Company, in this year's event held in Honolulu in April, fifty Ohana associates participated in the fundraiser and race to solve riddles and complete tasks while trying to be the first to cross the finish line. "Ohana is dedicated to serving our state's most vulnerable residents, and we were honored to come together to support Hospice Hawaii, and terminally ill individuals and their families," said Wendy Morriarty, State President of 'Ohana Health Plan. "The majority of our donation was raised by our dedicated and passionate associates who enable us to make a difference in the lives of thousands of Hawaii residents each day." The full analyst notes on WellCare are available to download free of charge at:

http://www.analystsreview.com/WCG.pdf/Register

--
NPS Pharmaceuticals, Inc. Analyst Notes
On May 22, 2014, NPS Pharmaceuticals, Inc. (NPS Pharma) announced that it will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014, at 11:30 a.m. ET in New York. According to the Company, a live webcast of the presentation will be available at NPS Pharma's website and a replay of the same will also be available three hours after the presentation concludes. The full analyst notes on NPS Pharma are available to download free of charge at:

http://www.analystsreview.com/NPSP.pdf/Register

--
Merrimack Pharmaceuticals Inc Analyst Notes
On May 22, 2014, Merrimack Pharmaceuticals Inc (Merrimack Pharmaceuticals) announced that it will present clinical data on its four novel antibody cancer therapeutics at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 to June 3, 2014, at McCormick Place in Chicago. Gavin MacBeath, Ph.D., Co-Founder and Senior Vice President at Merrimack said, "ASCO is an exciting opportunity for us to share the first Phase 2 clinical data from our systems biology-driven MM-121 program. We believe these data identify a biomarker-positive set of patients across multiple cancers who do not perform well on standard of care therapies but who may significantly benefit from co-administration of MM-121. These data also increase our confidence in our ongoing Phase 2 study of MM-111 in gastric cancer, where we are now prospectively evaluating a biomarker-positive population based on these new insights into ErbB3 biology. We also look forward to sharing Phase 1 data from our MM-141 and MM-151 programs as we seek to advance these therapies to Phase 2 development, along with our targeted nanoliposome MM-302." The full analyst notes on Merrimack Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/MACK.pdf/Register

--
CONMED Corporation Analyst Notes
On May 23, 2014, CONMED Corporation (CONMED) announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share which is payable on July 7, 2014, to all shareholders of record as of June 16, 2014. According to the Company, the Board projects that future cash dividends will be paid quarterly so that the total annual dividend rate based on the quarterly cash dividend will be $0.80 per share. CONMED added that any decision to pay future cash dividends will be subject to the Board's approval and will be based on the Company's future earnings, financial condition, and other relevant factors. The full analyst notes on CONMED are available to download free of charge at:

http://www.analystsreview.com/CNMD.pdf/Register

--
Haemonetics Corporation Analyst Notes
On May 23, 2014, Haemonetics Corporation (Haemonetics) announced that its CFO & Executive Vice President-Business Development, Chris Lindop, will present at The Jefferies 2014 Global Healthcare Conference on June 4, 2014, at 2:30 p.m. ET, in New York. According to the Company, a live webcast of the presentation can be accessed through Haemonetics' website. The full analyst notes on Haemonetics are available to download free of charge at:

http://www.analystsreview.com/HAE.pdf/Register

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED